Constitutional syndrome associated to metformin induced hepatotoxicty;Síndrome constitucional asociado a hepatotoxicidad por metformina

Gastroenterologia y Hepatologia

Volumn 31, Issue 10, 2008, Pages 643-645

  De La Poza Gómez, Gema ^a   Fernández, Miguel Rivero ^a   Romero, Manuel Vázquez ^a   Lapeña, Teresa Angueira ^a   De La Mata, Gemma Arranz ^a   De Miquel, Daniel Boixeda ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ATENOLOL; DIGOXIN; METFORMIN; SIMVASTATIN; TORASEMIDE;

AGED; ARTICLE; CASE REPORT; CHEMICAL ANALYSIS; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART DISEASE; HUMAN; HYPERTENSION; LACTIC ACIDOSIS; LIVER CLEARANCE; LIVER TOXICITY; MALE; ONCOLOGICAL PARAMETERS; SYNDROME;

EID: 60149107680     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/S0210-5705(08)75812-6     Document Type: Article

References (16)

1. Camargo R, Andrade RJ, Lucena MI. Hepatotoxicidad por fármacos utilizados en el control de la obesidad y trastornos metabólicos relacionados. Rev Esp Obes. 2006;4:17-23.
2. Cubuken A, Yilmaz MT, Satman I. Metformin kullanimina bagli bir akupt hepatit vakasi (metformin-induced hepatitis). Tip Fak Mecm. 1991;54:447-52.
3. Babich MM, Pike I, Shiffman ML. Metformin-induced acute hepatitis. Am J Med. 1998;104:490-2.
4. Nammour FE, Fayad NF, Pikin SR. Metformin-induced cholestatic hepatitis. Endocr Pract. 2003;4:307-9.
5. Kutoh E. Possible metformin-induced hepatotoxicity. Am J Geriatr Pharmacother. 2005;4:270-3.
6. Deutsch M, Kountouras D, Dourakis SP. Metformin hepatotoxicity. Ann Intern Med. 2004;140:408-9.
7. Desilets DJ, Shorr AF, Moran KA, Holtzmuller KC. Cholestatic jaundice associated with the use of metformin. Am J Gastroenterol. 2001;96:2257-8.
8. Bruguera M, Herrera S, Lázaro E, Madurga M, Navarro M, De Abajo FJ. Hepatitis aguda asociada al consumo de Copalchi. A propósito de 5 casos. Gastroenterol Hepatol. 2007;30:66-8.
9. Castell JV, Miñana MI. Hepatitis inducida por tóxicos. GH continuada. 2003;2:190-203.
10. Andrade RJ, Lucena MI. Toxicidad por medicamentos: detección y tratamiento. Gastroenterol Hepatol. 2005;28 Supl 1:1-11.
11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. J Clin Pharmacol Ther. 1981; 30:239-45.
12. García-Cortés M, Lucena MI, Pachkoria K, Borraz Y, Hidalgo R, Andrade RJ; Spanish Group for the Study of Drug-induced Liver Disease (grupo de Estudio para las Hepatopatías Asociadas a Medicamentos, Geham). Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther. 2008;27:780-9.
13. Danag G, Benichou C. Causality assessment of adverse reactions to drugs (II). A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:331-1336.
14. Lucena MI, García-Cortés M, Cueto R, López-Duran J, Andrade RJ. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol. 2008;22:141-58.
15. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266-70.
16. Mery CM, Duarte-Rojo A, Paz-Pineda F, Gómez E, Robles-Díaz G. ¿Modifica la colestasis la utilidad clínica del Ca 19-9 en el cáncer pancreatobiliar? Rev Invest Clin. 2001;53:511-7.